Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Document Type
- Journal article (11)
Language
- English (11)
Keywords
- Cushing’s syndrome (3)
- Cushing’s disease (2)
- hypercortisolism (2)
- metabolomics (2)
- ACTH (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CYP2W1 (1)
- Cushing's disease (1)
- NMR (1)
- NR3C1 (1)
- PPGL (1)
- USP8 (1)
- adenomas (1)
- adrenal (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenal tumours (1)
- autonomous cortisol secretion (1)
- blood pressure (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- catecholamines (1)
- comparability (1)
- confounders (1)
- cytoplasmic staining (1)
- deubiquitinases (1)
- dexamethasone suppression test (1)
- diagnosis (1)
- disease score (1)
- disease severity (1)
- dogs (1)
- drug therapy (1)
- ectopic (1)
- efficacy (1)
- endogenous hypercortisolism (1)
- feature selection (1)
- glucocorticoid excess (1)
- high dose dexamethasone suppression test (1)
- hormones (1)
- immune response (1)
- immunohistochemistry techniques (1)
- isturisa (1)
- machine learning (1)
- mass spectronomy (1)
- medical therapy (1)
- metyrapone (1)
- morbidity (1)
- mortality (1)
- multicenter (1)
- mutation (1)
- normal values (1)
- nuclear staining (1)
- operation (1)
- osilodrostat (1)
- paired (1)
- paraganglioma (1)
- pathogenesis (1)
- pheochromocytoma (1)
- pituitary adenomas (1)
- pituitary gland (1)
- plasma (1)
- plasma NMR (1)
- preanalytical conditions (1)
- protein expression (1)
- reference data (1)
- somatic mutations (1)
- surgical oncology (1)
- targeted metabolomics (1)
Institute
- Medizinische Klinik und Poliklinik I (11) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 633983 (2)
Purpose
Pheochromocytomas and Paragangliomas (PPGL) result in chronic catecholamine excess and serious health complications. A recent study obtained a metabolic signature in plasma from PPGL patients; however, its targeted nature may have generated an incomplete picture and a broader approach could provide additional insights. We aimed to characterize the plasma metabolome of PPGL patients before and after surgery, using an untargeted approach, and to broaden the scope of the investigated metabolic impact of these tumors.
Design
A cohort of 36 PPGL patients was investigated. Blood plasma samples were collected before and after surgical tumor removal, in association with clinical and tumor characteristics.
Methods
Plasma samples were analyzed using untargeted nuclear magnetic resonance (NMR) spectroscopy metabolomics. The data were evaluated using a combination of uni- and multi-variate statistical methods.
Results
Before surgery, patients with a nonadrenergic tumor could be distinguished from those with an adrenergic tumor based on their metabolic profiles. Tyrosine levels were significantly higher in patients with high compared to those with low BMI. Comparing subgroups of pre-operative samples with their post-operative counterparts, we found a metabolic signature that included ketone bodies, glucose, organic acids, methanol, dimethyl sulfone and amino acids. Three signals with unclear identities were found to be affected.
Conclusions
Our study suggests that the pathways of glucose and ketone body homeostasis are affected in PPGL patients. BMI-related metabolite levels were also found to be altered, potentially linking muscle atrophy to PPGL. At baseline, patient metabolomes could be discriminated based on their catecholamine phenotype.